Synlogic, Inc., 301 Binney Street, Cambridge, MA, 02142, USA.
Nat Commun. 2020 Apr 8;11(1):1738. doi: 10.1038/s41467-020-15508-1.
A complex interplay of metabolic and immunological mechanisms underlies many diseases that represent a substantial unmet medical need. There is an increasing appreciation of the role microbes play in human health and disease, and evidence is accumulating that a new class of live biotherapeutics comprised of engineered microbes could address specific mechanisms of disease. Using the tools of synthetic biology, nonpathogenic bacteria can be designed to sense and respond to environmental signals in order to consume harmful compounds and deliver therapeutic effectors. In this perspective, we describe considerations for the design and development of engineered live biotherapeutics to achieve regulatory and patient acceptance.
许多疾病都存在代谢和免疫机制的复杂相互作用，这些疾病代表了未满足的重大医疗需求。人们越来越认识到微生物在人类健康和疾病中的作用，并且有证据表明，一类由工程微生物组成的新型活体生物疗法可以针对疾病的特定机制。利用合成生物学的工具，可以设计非致病性细菌来感知和响应环境信号，以消耗有害化合物并传递治疗效应物。在这篇观点文章中，我们描述了设计和开发工程活体生物疗法以实现监管和患者接受的考虑因素。
